0.70Open0.70Pre Close0 Volume2.67K Open Interest9.00Strike Price0.00Turnover118.83%IV17.00%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.70Extrinsic Value100Contract SizeAmericanOptions Type-0.3040Delta0.1186Gamma14.81Leverage Ratio-0.0227Theta-0.0021Rho-4.50Eff Leverage0.0087Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet